Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02617472 · ClinicalTrials.gov registry record · NA
Effectiveness of Kegel Exercise Device in Strengthening Pelvic Floor and Treating Urinary Incontinence (UI)
A NA study of Stress Urinary Incontinence and Sexual Dysfunction, sponsored by Lelo.
- Completed
- Registry status
- NA
- Development phase
- 93
- Enrollment target
- 1
- Study location
NCT02617472: Completed NA study of Stress Urinary Incontinence and Sexual Dysfunction, sponsored by Lelo.
NCT02617472 is a NA study of Stress Urinary Incontinence and Sexual Dysfunction that has completed, run by Lelo. The registered enrollment target is 93 participants, below the 160-participant average among 35 other Stress Urinary Incontinence trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02617472, a NA study of Stress Urinary Incontinence and Sexual Dysfunction, has completed, sponsored by Lelo.
- COMPLETED
- Registry status
- NA
- Development phase
- 93 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the effectiveness of a new pelvic floor exercise device in strengthening pelvic floor muscles and treating urinary incontinence among women who are experiencing symptoms of pelvic floor weakness. The study will be conducted over 12 weeks and results will be collected through self-assessment questionnaires and clinical pelvic examination. Effectiveness outcomes will be tracked over the duration of the trial and measured against historical symptoms.
Primary Outcome
Pelvic floor strength measured by a clinical perineometer in cm H2O. A baseline measurement of resting and peak muscle contraction values will be recorded at the start before the intervention and after the 12 weeks of treatment.
Conditions Studied
Interventions
- DEVICE Pelvic floor exerciser
Study Locations (1)
Arizona
- Banner University Medical Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-08 |
| Phase | NA |
What the finished NCT02617472 record still lists
NCT02617472 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 160-participant average among 35 other Stress Urinary Incontinence trials with a reported enrollment target (42% lower).
The record links to 2 conditions, with Stress Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Pelvic floor exerciser is the first listed.
NCT02617472 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT02617472 about?
NCT02617472 is a clinical study titled "Effectiveness of Kegel Exercise Device in Strengthening Pelvic Floor and Treating Urinary Incontinence (UI)". This study will assess the effectiveness of a new pelvic floor exercise device in strengthening pelvic floor muscles and treating urinary incontinence among women who are experiencing symptoms of pelvic floor weakness. The study will be conducted over 12 weeks and results will be collected through s...
What is the current status of trial NCT02617472?
This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2015-11. Estimated completion is 2017-08.
What conditions does trial NCT02617472 study?
This clinical trial studies the following conditions: Stress Urinary Incontinence, Sexual Dysfunction.
What interventions are being tested in trial NCT02617472?
The interventions under investigation include: Pelvic floor exerciser (DEVICE).
Who is sponsoring clinical trial NCT02617472?
This trial is sponsored by Lelo, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02617472 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02617472's enrollment target sits among peer trials
93 19th of 35 higher than 17 of 35 other Stress Urinary Incontinence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stress Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ProACT Post-Approval Study
RECRUITING · NA
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
Comparison of Virtual Pelvic Floor Physical Therapy With a Pelvic Floor Trainer in the Treatment of Stress Urinary Incontinence.
RECRUITING · NA
-
Impact of Unrestrictive Exercise Following Mid-Urethral Sling Surgery
RECRUITING · NA
-
Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy
RECRUITING · NA
-
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia